Sara Bringhen

685 citations
4 papers · 397 indexed · 1 hit paper · h-index 3
Topics
Multiple Myeloma Research and Treatments (4 papers)Protein Degradation and Inhibitors (2 papers)Peptidase Inhibition and Analysis (2 papers)
Partner nations
ItalySpainUnited States

In The Last Decade

Sara Bringhen

3 papers receiving 390 citations

Hit Papers

Lenalidomide Maintenance After Autologous Stem-Cell Trans...20172026202020232017100200300

Peers

Sara Bringhen
Comparison fields: 5 of 36
  • Hematology 376
  • Molecular Biology 310
  • Oncology 224
  • Genetics 35
  • Pathology and Forensic Medicine 15
Replace Antonio Palumbo with:
Antonio Palumbo Netherlands
Eileen Liao United States
Clotilde Cangialosi Italy
Miguel Teodoro Hernández‐Garcia Spain
Marti McKinley United States
Cecilia Rus Italy
Pia Sondergeld Germany
Evžen Gregora Czechia
Agne Paner United States
Kathryn McDonnell United States
Sara Bringhen relative to Antonio Palumbo Netherlands Antonio Palumbo's profile →
Citations per field
00.5×1.5×
Antonio Palumbo · 1×
Citations per year

Countries citing papers authored by Sara Bringhen

Since Specialization
Citations

This map shows the geographic impact of Sara Bringhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Bringhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Bringhen more than expected).

Fields of papers citing papers by Sara Bringhen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Bringhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Bringhen. The network helps show where Sara Bringhen may publish in the future.

Co-authorship network of co-authors of Sara Bringhen

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Bringhen. A scholar is included among the top collaborators of Sara Bringhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Bringhen. Sara Bringhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

About Sara Bringhen

Sara Bringhen is a scholar working on Hematology, Oncology and Molecular Biology, having authored 4 papers that have together received 397 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (2 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Hematology (376 citations), Oncology (224 citations) and Molecular Biology (310 citations). Sara Bringhen has collaborated with scholars based in Italy, Spain and United States. Frequent co-authors include Gérald Marit, Sarah A. Holstein, Cyrille Hulin, Sin‐Ho Jung, Kenneth C. Anderson, Zhinuan Yu, Pellegrino Musto, Benjamin Winograd, Robert Knight and D. Caillot. Their work appears in journals such as Journal of Clinical Oncology, Hematology and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026